Browse the evidence

Next-generation multi-receptor agonists (e.g., Tirzepatide, a dual GLP-1/GIP agonist) offer superior weight loss and metabolic efficacy compared to single GLP-1RAs.

If single GLP-1 medications (like Ozempic or Wegovy) aren't providing enough weight loss or metabolic improvement, ask your doctor about dual-agonists like Tirzepatide. These newer drugs target two hormones (GLP-1 and GIP) and have shown even greater weight loss in clinical trials. They are approved for both diabetes and obesity management.

Daily protein supplementation (12g additional protein via skimmed milk/soy isolate) combined with simple calisthenic and aerobic exercise for 8 weeks significantly increases lean mass and appendicular muscle mass in healthy sedentary adults.

If you are sedentary and want to build muscle, you don't need a gym membership or expensive gear. Add 12g of protein daily (e.g., via a supplement or food) and perform simple bodyweight exercises (like squats and push-ups) 3 times a week, plus walk 150 minutes a week. Doing this for 8 weeks will likely increase your lean muscle mass.

Lengthened partial repetitions (LPs) elicit similar muscle hypertrophy and strength-endurance adaptations as full range of motion (ROM) repetitions in resistance-trained individuals.

If you are a trained lifter, you don't need to force full range of motion if it causes pain or joint issues. You can use lengthened partial reps (starting from the stretched position and going halfway up) and still build muscle and strength just as well as doing full reps. Just make sure you are training to failure and emphasizing the stretch.

Diet and lifestyle interventions reduce waist circumference regardless of TCF7L2 genotype, though the genotype does not modify this specific outcome.

You do not need to worry about your TCF7L2 genotype when it comes to losing belly fat. Standard diet and lifestyle changes will reduce waist circumference for everyone, regardless of whether you carry the risk allele. Focus on sustainable energy balance and activity.

GCGR/GLP-1 dual agonists (e.g., mazdutide, survodutide) and GCGR/GLP-1/GIP triple agonists (e.g., retatrutide) elicit substantial body weight reduction (up to 24.2%) and improve liver health in patients with obesity and MASLD/MASH.

For individuals with obesity and liver fat, newer once-weekly injections targeting the glucagon and GLP-1 receptors (and sometimes GIP) are showing remarkable results, with some patients losing over 20% of their body weight and seeing improvements in liver health. These are prescription medications requiring medical supervision, but they represent a significant advancement over older treatments.

Back squat training produces greater thigh hypertrophy (quadriceps and adductors) compared to hip thrust training.

If you want bigger quads and inner thighs, you need to do squats. Hip thrusts are great for glutes, but they don't build the rest of your legs as well as squats do.

Semaglutide (2.4 mg once-weekly) significantly reduces the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its components (steatosis, inflammation, ballooning) in patients with overweight/obesity and type 2 diabetes compared to placebo.

If you have overweight/obesity and type 2 diabetes, semaglutide (2.4 mg weekly) is a clinically proven treatment to significantly reduce liver fat, inflammation, and scarring (MASH/MASLD) compared to placebo. This is particularly relevant if lifestyle changes alone have not resolved liver issues. The treatment involves a weekly injection and is supported by strong statistical evidence from large clinical trials.

Retatrutide (12mg weekly) achieves 24.2% weight loss, rivaling bariatric surgery outcomes.

Retatrutide 12mg weekly can lead to ~24% weight loss. This is the highest efficacy reported in this review, rivaling surgery.

CagriSema (Cagrilintide + Semaglutide) achieves 22.7% weight loss, outperforming semaglutide alone.

CagriSema, a combination of Cagrilintide and Semaglutide, can lead to ~23% weight loss. It is more effective than Semaglutide alone.

GLP-1 receptor agonists (e.g., tirzepatide, danuglipron) produce significant weight loss and glycemic improvement in type 2 diabetes and obesity, with weight loss and glycemic effects being partially independent mechanisms.

GLP-1 based medications like tirzepatide are highly effective for weight loss (15-21%) and blood sugar control. Be aware that gastrointestinal side effects are common and may lead some to stop treatment, but the dual benefit is significant. Discuss dosing strategies with your provider to manage side effects.

A supervised 16-week strength training program performed at 70% 1RM with high volume induces significant strength gains, lean body mass increases, and favorable cardiac remodeling (LV/LA enlargement without functional impairment) in previously untrained women, with magnitude of adaptation similar to or exceeding that of men.

Perform supervised strength training 3 times a week at 70% of your one-rep max. Focus on compound movements (squats, presses, rows). Expect significant strength and lean mass gains within 16 weeks, comparable to men, along with improved heart health markers like ventricular enlargement without functional loss.

Sustained weight loss of 10% or more over five years is associated with a significantly higher likelihood of achieving biochemical remission of type 2 diabetes, even in patients with advanced disease and established complications.

If you have type 2 diabetes, losing 10% of your body weight over a few years significantly increases your chances of reversing the disease, even if you have had it for a long time or have other health issues. You do not need expensive clinical programs to achieve this; sustained, modest weight loss in routine life is effective. Focus on maintaining this weight loss, as remission is defined by stable blood sugar without medication.

Among adherent participants (completing ≥80% of coaching calls), the same remote weight loss intervention resulted in significant weight loss compared to non-adherent participants.

If you can commit to the full program, including regular check-ins, significant weight loss is possible. The key is adherence, which may require more support or tailored engagement strategies for cancer survivors.

Autoregulated training using Repetitions in Reserve (RIR)-based Rating of Perceived Exertion (RPE) provides small advantages for improving 1RM strength compared to traditional percentage-based 1RM loading in resistance-trained males.

If you are a trained lifter, try using RPE (Repetitions in Reserve) to guide your weights instead of strict percentages. On good days, you might lift heavier; on bad days, lighter. This approach likely offers a small edge in strength gains over rigid percentage plans, though the difference isn't huge. Focus on how hard the lift feels (aiming for a specific RPE) rather than a fixed number on the bar.

In patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), achieving a baseline Body Mass Index (BMI) of 30 kg/m² or higher is a significant independent predictor of achieving clinically relevant weight loss (≥7% of initial body weight) through lifestyle interventions.

If you have MASLD and a BMI of 30 or higher, you are statistically more likely to achieve significant weight loss through lifestyle changes than someone with a lower BMI. This is likely due to higher energy expenditure at rest. Use this advantage by committing to the lifestyle changes early, as your body is primed to respond to caloric deficits more robustly than those with lower baseline weights.

Utilization of Glucagon-like peptide-1 (GLP-1) receptor agonists for Type 2 Diabetes is a significant independent predictor of achieving relevant weight loss (≥7%) in MASLD patients, with odds ratios increasing for greater weight loss thresholds.

If you have MASLD and Type 2 Diabetes, using a GLP-1 agonist significantly increases your chances of losing enough weight to improve your liver health. The data shows that users are over 4 times more likely to lose 10% or more of their body weight compared to non-users. Discuss this option with your doctor as part of a comprehensive MASLD management plan.

Engagement with a nutritionist is a significant independent predictor of achieving relevant weight loss (≥7% and ≥10%) in MASLD patients, even when controlling for baseline BMI and other comorbidities.

If you have MASLD, seeking help from a qualified nutritionist significantly increases your chances of losing enough weight to improve your liver health. The study shows that patients who worked with a nutritionist were nearly 4 times more likely to lose 10% or more of their body weight. Make this a priority in your care plan.

GLP-1 receptor agonists (GLP-1RAs) as adjunctive therapy to insulin significantly reduce body weight, HbA1c, and total daily insulin requirements in patients with type 1 diabetes and overweight or obesity.

If you have Type 1 Diabetes and are overweight, adding a GLP-1RA (like semaglutide or liraglutide) to your insulin regimen can help you lose weight (average 4-6 kg), lower your HbA1c slightly, and significantly reduce your daily insulin needs (by ~9 units). This is generally safe, though you may experience temporary nausea and a slightly higher risk of low blood sugar, which can be managed by adjusting your insulin dose.

Semaglutide demonstrates superior efficacy in reducing body weight, HbA1c, and insulin requirements compared to other GLP-1RAs (liraglutide, exenatide) in patients with Type 1 Diabetes.

Among GLP-1RAs, semaglutide (1.0 mg weekly) appears to be the most effective option for Type 1 Diabetes patients, offering greater weight loss (~6 kg) and insulin reduction (~15 units/day) compared to liraglutide or exenatide. Discuss with your provider if you are a candidate for this specific agent.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces dose-dependent reductions in body weight (up to 9.8% at 45 mg) and waist circumference, with maximal efficacy observed at higher doses (24-45 mg).

Orforglipron is an oral medication that helps obese adults lose weight and improve metabolic markers like blood sugar and cholesterol. It works by mimicking a natural hormone (GLP-1) to reduce appetite and slow digestion. The higher the dose (up to 45 mg daily), the more weight is lost, with studies showing up to 9.8% body weight reduction. However, higher doses also increase the risk of stomach issues like nausea and diarrhea, which may lead some patients to stop taking it. It is taken once daily without strict fasting requirements, making it more convenient than some injectable alternatives.

Lifestyle interventions (diet and exercise) are effective in preventing or delaying Type 2 Diabetes in high-risk groups, including those with a history of GDM, but adherence remains a significant barrier.

For women with a history of GDM, aiming for 150 minutes of physical activity per week combined with dietary changes is the most effective way to prevent Type 2 Diabetes. Structured programs offering health coaching and group support can improve adherence and outcomes. Regular monitoring of HbA1c and fasting plasma glucose is recommended.

Treatment with semaglutide 2.4 mg for overweight or obesity leads to a statistically significant reduction in the need for concomitant antihypertensive and lipid-lowering medications compared to placebo, primarily through weight-loss-mediated improvements in blood pressure and lipid profiles.

If you are taking medication for high blood pressure or high cholesterol, significant weight loss achieved through semaglutide 2.4 mg may allow your doctor to safely lower your dose or stop the medication entirely. This is not automatic; it requires active monitoring by your healthcare provider to ensure your blood pressure and lipids remain in a healthy range without the drugs. Do not stop these medications on your own.

Intentional weight loss achieved through lifestyle interventions, antiobesity medications, or bariatric surgery reduces the incidence of obesity-associated cancers, particularly hormone-dependent malignancies in postmenopausal women.

If you have overweight or obesity, achieving and maintaining a weight loss of at least 5% of your body weight can significantly reduce your risk of developing certain cancers, especially in postmenopausal women. This can be achieved through lifestyle changes (diet and exercise), medications, or surgery. The key is sustained loss, not just short-term dieting.

Protein supplementation combined with resistance exercise increases muscle mass and strength, but intakes above 1.6 g/kg body weight per day provide no additional significant gains.

To build muscle, combine resistance training with protein intake of 1.6 g/kg body weight per day. Eating more protein than this does not provide additional muscle or strength gains.